Top Markets
Coin of the day
Midatech Pharma plc Midatech Pharma plc

Midatech Pharma plc

MTPH
주식 순위 #42756
Midatech Pharma plc operates as a pharmaceutical company specializing in drug... Midatech Pharma plc operates as a pharmaceutical company specializing in drug delivery technologies. Its core activities revolve around the research and development of therapeutic compounds, with operations spanning the United Kingdom, broader Europe, and global markets. Currently, its pipeline includes several key developments: MTX110, an innovative direct-delivery therapy targeting diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immunosuppressant designed for topical use against psoriasis; MTD211, a sustained-release version of brexpiprazole intended for managing schizophrenia and as an add-on therapy for major depressive disorder; and MTD219, a prolonged-action formulation of tacrolimus aimed at reducing the likelihood of organ transplant rejection. Beyond its specific drug candidates, Midatech Pharma provides advanced drug delivery platforms. These include Q-Sphera, a microtechnology based on polymer microspheres that enables drugs to be released over extended periods; MidaSolve, a nanotechnology employing oligosaccharides to enhance drug solubility, allowing direct and localized administration into tumors; and MidaCore, a gold nanoparticle system engineered to precisely deliver chemotherapeutic or immunotherapeutic agents to disease sites. Established in 2000, the company maintains its headquarters in Cardiff, United Kingdom.
주가
$0.05309195
마지막 동기화: 2023-04-24
시가총액
$164.43
변동 (1일)
0.46%
변동 (1년)
0.00%
국가
GB
거래 Midatech Pharma plc (MTPH)

카테고리

Midatech Pharma plc (MTPH)의 매출
Aug 2026 기준 매출 TTM: 0
Midatech Pharma plc의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Midatech Pharma plc의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B -
US
$6.02B -
NL
- -
CH
$10.11B -
BE
- -
KR